Trade name:

International name:
Daklizumab (Daclizumab)

Group Affiliation:

Description of the active substance (INN):

Dosage Form:
Concentrate for solution for infusion

Mode of action:
Selective immunosuppressant, is a recombinant antibody IgG1 (anti-Tas) acting as receptor blockers to interleykinu2. It is specific binds to the alpha-subunit receptor complex vysokoaffinnogo interleykina2 (which is expressed on activated T-cells) and inhibits the binding and its biological activity. Inhibits interleykinom2 mediated activation of lymphocytes (link in the pathogenesis of immune response that underlies the rejection of the transplant). In the recommended doses saturates the receptor subunit vysokoaffinnogo receptor complex interleykina2 within 90 days. There is no marked changes in the number of circulating lymphocytes, or cell phenotypes, except for transient decrease in Tas- positive cells. Reduces the frequency of histologically confirmed acute renal allograft rejection within 6 months after transplantation and significantly prolongs the time before the first episode of rejection. Increasing the frequency of rejection after the cancellation is not marked.

Prevention of acute graft rejection reaction kidneys (consisting of combined immunosuppressive therapy with cyclosporine and GCS).


Side effects:
On the part of the digestive system: nausea, vomiting, diarrhea or constipation, abdominal pain, stomachalgia, flatulence, gastritis, hemorrhoids. On the part of the SSA: the reduction and / or raising blood pressure, tachycardia, thrombosis. The nervous system: weakness, dizziness, headache pain, insomnia, depression and anxiety, epileptic syndrome, tremor. On the part of the urinary system: oliguria, dysuria, nefronekroz, nephrotoxicity, hydronephrosis, bleeding from urinary tract, renal failure, peripheral edema, urinary retention. the respiratory system: dyspnea, pulmonary edema, cough, pulmonary atelectasis, chronic pneumonia, pharyngitis, rhinitis, hypoxia, pleural effusion. From a musculoskeletal: myalgia, ossalgiya, arthralgia, pain in the lumbar spine. Allergic reactions: chills, fever, itching, skin rash, anaphylactoid reaction. Local reaction: flushing, pain at the injection site, lymphocele. Other: poor wound healing, acne, hirsutism, increased sweating, hyperglycemia, phlegmon, visual disturbances.

Dosage and administration:
B / c, for 15 minutes in the peripheral or central vein. Adults and children first injection is carried out for 24 hours before transplantation at a dose of 1 mg / kg. Concentrate is diluted 0.9% NaCl solution to 50 ml. Mixing solutions can not shake the vial to avoid foaming, and should take measures to ensure the sterility of prepared diluted solution. Infusion solution should be used within 4 h after preparation, if the solution should be kept longer (up to 24 h), it should be kept in a refrigerator at 2-8 grad.S. The second and each subsequent doses given at intervals of 14 days in total - 5 doses.

The introduction of the drug should be performed only in a qualified medical facility. Dose adjustment in severe chronic renal failure is not required. Patients receiving immunosuppressants after organ transplantation have an increased risk of lymphoproliferative disease and opportunistic infections. Women of reproductive age should use effective methods of contraception for 4 months after last injection.

Pharmaceutical incompatible with other solutions. Compatible with cyclosporine, mycophenolate mycophenolate, ganciclovir, acyclovir, azathioprine, antithymocyte Ig, muromonabom-CD3 (OKT3), SCS.

Description Zenapaks product is not intended for purposes of treatment without the participation of a physician.